Liquidia (NASDAQ:LQDA) Downgraded by Zacks Research to Hold

Zacks Research lowered shares of Liquidia (NASDAQ:LQDA) from a strong-buy rating to a hold rating in a research note issued to investors on Thursday,Zacks.com reports.

LQDA has been the topic of several other research reports. Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Royal Bank Of Canada set a $130.00 price objective on shares of Liquidia in a report on Friday, July 24th. Bank of America lifted their price objective on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Thursday. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 target price on shares of Liquidia in a report on Monday, May 11th. Finally, Lifesci Capital lowered Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $98.08.

Liquidia Stock Performance

NASDAQ:LQDA opened at $74.44 on Thursday. The stock has a market cap of $6.62 billion, a P/E ratio of 54.34 and a beta of 0.58. The firm’s fifty day simple moving average is $78.67 and its 200 day simple moving average is $55.13. Liquidia has a twelve month low of $21.15 and a twelve month high of $93.61. The company has a quick ratio of 2.03, a current ratio of 2.31 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same period in the previous year, the firm posted ($0.49) earnings per share. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year. As a group, research analysts predict that Liquidia will post 2.74 EPS for the current year.

Insider Activity

In related news, Director Paul B. Manning sold 200,000 shares of Liquidia stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the completion of the transaction, the director directly owned 716,311 shares of the company’s stock, valued at $45,779,436.01. This trade represents a 21.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Stephen M. Bloch sold 242,269 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the sale, the director directly owned 1,176,184 shares in the company, valued at $82,838,639.12. The trade was a 17.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 1,756,861 shares of company stock valued at $122,981,112. 25.60% of the stock is owned by company insiders.

Institutional Trading of Liquidia

Hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after buying an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Liquidia by 10.7% during the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after buying an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after buying an additional 16,022 shares during the last quarter. Creative Planning raised its stake in Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after buying an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after acquiring an additional 11,111 shares in the last quarter. 64.54% of the stock is owned by institutional investors.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove second-quarter revenue to $171.68 million, exceeding the $168.48 million consensus estimate, while revenue increased more than 1,800% year over year. Management also highlighted rising demand for the inhaled lung-disease treatment. LQDA Q2 Earnings Top
• Positive Sentiment: Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share and helps fund a broader inhaled-treprostinil pipeline, providing investors with a significant long-term growth narrative. LQDA Earnings Call Highlights
• Positive Sentiment: Bank of America raised its price target from $79 to $92, while BTIG Research and Needham indicated further appreciation potential. These targets support the bullish case, although Bank of America retained a neutral rating. Bank of America Price Target
• Neutral Sentiment: Lifesci Capital initiated or maintained a Market Perform view, reflecting more balanced expectations despite the company’s strong commercial momentum. Lifesci Capital Rating
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share narrowly missed the $0.76 consensus estimate. The results triggered a negative reaction despite the revenue beat, particularly after LQDA had already risen sharply this year. Liquidia Shares Gap Down
• Negative Sentiment: HC Wainwright lowered its third-quarter 2026 EPS forecast to $1.01 from $1.15, adding pressure to near-term expectations. With a reported price-to-earnings ratio above 54, investors may be particularly sensitive to estimate reductions. HC Wainwright Estimate Revision

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).